Publication at Faculty of Medicine in Pilsen |
2021
Abstract
The current availability of modern next-generation androgen receptor inhibitors (enzalutamide, apalutamide and now also darolutamide) has fundamentally changed the possibilities of the procedure in order to significantly prolong metastasis-free survival in patients with castration-resistant non-metastatic prostate cancer. Consideration of the safety profile of treatment and the patient's risk of cancer as well as possible side effects of treatment is very important in this disease.